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Abstract
Background
The efficacy of first-generation protease inhibitor based triple-therapy against hepatitis C
virus (HCV) infection is limited in HIV/HCV-coinfected patients with advanced liver fibrosis
and non-response to previous peginterferon-ribavirin. These patients have a low chance of
achieving a sustained virologic response (SVR) using first generation triple-therapy, with a
success rate of only 20%. We investigated the efficacy and safety of lead-in therapy with
intravenous silibinin followed by triple-therapy in this difficult-to-treat patient group.
Methodology
Inclusion criteria were HIV/HCV coinfection with advanced liver fibrosis and documented
previous treatment failure on peginterferon-ribavirin. The intervention was a lead-in therapy
with intravenous silibinin 20 mg/kg/day for 14 days, followed by triple-therapy (peginter-
feron-ribavirin and telaprevir) for 12 weeks, and peginterferon-ribavirin alone for 36 weeks.
Outcome measurements were HCV-RNA after silibinin lead-in and during triple-therapy,
SVR data at week 12, and safety and tolerability of silibinin.
Results
We examined sixteen HIV/HCV-coinfected patients with previous peginterferon-ribavirin
failure, of whom 14 had a fibrosis grade METAVIRF3. All were on successful antiretroviral
therapy. Median (IQR) HCV-RNA decline after silibinin therapy was 2.65 (2.1–2.8) log10
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copies/mL. Fifteen of sixteen patients (94%) had undetectable HCV RNA at weeks 4 and
12, eleven patients (69%) showed end-of-treatment response (i.e., undetectable HCV-RNA
at week 48), and ten patients (63%) reached SVR at week 12 (SVR 12). Six of the sixteen
patients (37%) did not reach SVR 12: One patient had rapid virologic response (RVR) (i.e.,
undetectable HCV-RNA at week 4) but stopped treatment at week 8 due to major depres-
sion. Five patients had RVR, but experienced viral breakthroughs at week 21, 22, 25, or 32,
or a relapse at week 52. The HIV RNA remained below the limit of detection in all patients
during the complete treatment period. No serious adverse events and no significant drug-
drug interactions were associated with silibinin.
Conclusion
A lead-in with silibinin before triple-therapy was safe and highly effective in difficult-to-treat
HIV/HCV coinfected patients, with a pronounced HCV-RNA decline during the lead-in
phase, which translates into 63% SVR. An add-on of intravenous silibinin to standard of
care HCV treatment is worth further exploration in selected difficult-to-treat patients.
Trial Registration
ClinicalTrials.gov NCT01816490
Introduction
Treatment of hepatitis C virus (HCV) infection has currently entered a new era [1,2]. The
availability of next-generation direct-acting antiviral drugs (DAAs) against HCV makes a cure
possible for the majority of patients infected with HCV, almost regardless of HIV coinfection,
fibrosis stage, previous response to standard of care therapy or genetic variations in the inter-
leukin genotype [3–9]. However, using early DAAs, physicians were challenged by the limited
efficacy and the high toxicity of first-generation HCV protease inhibitor based triple-therapy
(i.e., telaprevir or boceprevir combined with peginterferon-ribavirin) [10], significant drug-
drug interactions and the high pill burden which compromised patient adherence.
In 2011, we investigated as a proof of concept the effect of intravenous silibinin—an extract
of the milk thistle silybum marinum and commercially available as Legalon SIL—on
HCV-RNA decline and treatment outcome in HIV/HCV coinfected patients with advanced
liver fibrosis/cirrhosis and previous failure of peginterferon-ribavirin therapy. These patients
are most in need of immediate therapy as they are at highest risk for HCV-related morbidity
and mortality [11]. We added intravenous silibinin as lead-in prior to triple-therapy in 16
HIV/HCV-coinfected patients with advanced liver fibrosis who had failed on previous pegin-
terferon-ribavirin therapy. Encouraged by the excellent virologic responses of the first six pilot
patients with a sustained virologic response (SVR) rate of 80% at week 24, we felt it important
to share these data, published in June 2014 [12]. Here, we show the data about treatment out-
comes and drug concentrations in all 16 patients.
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Methods
Objectives
With this proof of concept study we aimed to assess the virologic outcomes of the lead-in with
intravenous silibinin and the subsequent triple-therapy (i.e., telaprevir in combination with
peginterferon-ribavirin), as well as the safety and tolerability of silibinin in HIV/HCV-coin-
fected patients with advanced liver fibrosis who failed on previous treatment with peginter-
feron-ribavirin.
Study design and patient selection
Between May 2012 and October 2012 we prospectively enrolled six individuals coinfected with
HIV/HCV genotype 1 within the pilot study called PRE-THISTLE. The outcome of these six
patients has been previously published [12]. After that, between April 2013 and November
2013, we included another ten individuals coinfected with HIV/HCV genotype 1 in the THIS-
TLE trial–the HIV/HCV silibinin trial, which is a phase II, multi-center, open-label, interven-
tional study to evaluate the safety of intravenous silibinin and its effect on the hepatitis C
virus load in treatment-experienced HIV/HCV coinfected individuals with advanced liver
fibrosis in the Swiss HIV Cohort Study (SHCS) (http://clinicaltrials.gov, ID NCT01816490)
(Fig 1 and data in S1 and S2 Files). The authors confirm that all ongoing and related trials for
this drug/intervention are registered. Based on our inclusion and exclusion criteria we selected
16 patients within the SHCS who were eligible for the study. We did not evaluate further
enrollment of patients since newer, better tolerable, and more effective DAAs became available
at that time. The overall study duration was 15 days (i.e., the time-period including the admin-
istration of intravenous silibinin). Subsequent to THISTLE (i.e., at day 15) the study-subjects
were included in SHCS trial #688. Trial #688 investigated the occurrence of HCV-resistance
to the HCV protease inhibitors during triple-therapy. The duration of trial #688 was 48 weeks
with a follow-up of 12 weeks (i.e., SVR 12 data). For the pilot (PRE-THISTLE) study, all six
patients were enrolled at the University Hospital Zurich, University of Zurich. For the THSTLE
trial, six patients were recruited at the University Hospital Zurich, University of Zurich, and
four patients at the Bern University Hospital, University of Bern.
We treated all 16 patients (14 men and two women) with an intravenous silibinin lead-in
and subsequently initiated triple-therapy. Patient selection was based on documented advanced
liver fibrosis and a documented history of previous failure of standard-of-care peginterferon-
ribavirin, including three different scenarios: (i) non-response (i.e., less than 2 log10 IU/mL
decrease in HCV RNA from baseline to week 12 of therapy), (ii) partial response (i.e., more
than 2 log10 IU/mL decrease in HCV RNA at week 12, but detectable HCV RNA at week 24) or
(iii) viral breakthrough (i.e., undetectable HCV RNA at week 24, but detectable HCV RNA
during treatment). Advanced liver fibrosis was defined as a METAVIR fibrosis score2 in at
least one documented liver biopsy since diagnosis of HCV infection. SVR at week 12 is defined
as an undetectable HCV RNA level 12 weeks after the end of treatment. Of note, a SVR 12 cor-
relates strongly with a permanent clearance of the virus and predicts a cure in 99 to 100% of
patients. [13]
The ethical committee of the Canton Zurich approved the THISTLE trial on January 15th
2013. A study amendement was approved by the ethical committee of the Canton Zurich on
June 3th 2013. Written informed consent was given by all study participants.
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Investigational product and mode of treatment
Intravenous silibinin has been commercially available as silibinin-C-2’, 3-dihydrogen succinate
disodium salt (i.e., Legalon SIL) for 30 years for the treatment of hepatic intoxication by Ama-
nita phalloides. In Austria, Legalon SIL was approved in December 2010 for treatment of
Fig 1. Flowchart of sixteen HIV/HCV coinfected patients allocated to a lead-in with intravenous silibinin.
doi:10.1371/journal.pone.0133028.g001
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chronically HCV-infected patients with non-response or partial response to peginterferon-
ribavirin. In Switzerland, Legalon SIL is accepted for compassionate use for the same indica-
tion. All patients received lead-in therapy with intravenous silibinin at 20 mg/kg/day once
daily for 14 days. Silibinin was administrated over one hour. After the 14-day intravenous sili-
binin lead-in treatment, patients started standard triple-therapy on day 15 (i.e. week 0), includ-
ing telaprevir 375mg TID, pegylated interferon alfa-2a 180μg once a week, and weight-based
daily ribavirin 1000mg (body weight<65kg) or 1200mg (body weight65kg). Triple-therapy
was continued for 12 weeks, followed by 36 weeks of peginterferon-ribavirin dual therapy.
Assessment of HCV RNA, silibinin safety and tolerability
Laboratory assessments to ensure drug safety were made on days 1, 8, 12, and 15 of intravenous
silibinin lead-in, and during subsequent triple therapy in weeks 1, 2, 4, 12, 24, 36, and 48, and
additionally according to patient’s clinical state. These assessments included measurements of
full blood count, electrolytes (sodium, potassium), aspartate aminotransferase, alanine amino-
transferase, total and fractionated bilirubin, gamma-glutamyl transferase, total protein, alkaline
phosphatase, creatinine, albumin, and international normalized ratio (INR). Serum HCV RNA
levels were determined by the TaqMan PCR assay (Roche COBAS TaqMan v2.0, limit of detec-
tion 15 IU/mL). HCV RNA was measured on days 1, 8, and 15 of silibinin treatment. During
triple-therapy, HCV viral load was monitored at weeks 2, 4, and 12. The tolerability of intrave-
nous silibinin was determined by daily clinical assessment during the silibinin treatment
period.
Antiretroviral and silibinin drug levels
Plasma samples obtained from HIV-HCV infected individuals were isolated by immediate cen-
trifugation at 1850 X g (3000 rpm) and stored at -80°C. For the plasma quantification of antire-
troviral drugs, samples were inactivated for virus at 60°C for 60 minutes. Plasma levels were
determined by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)
after protein precipitation with acetonitrile according to our previously reported validated ana-
lytical method [14]. The laboratory participates in an international external quality assurance
program for antiretroviral drugs analysis (KKGT, Stichting Kwaliteitsbewaking Klinische Gen-
eesmiddelanalyse en Toxicologie, Association for Quality Assessment in TDM and clinical
Toxicology, The Hague, The Netherlands). Plasma trough levels for raltegravir (RAL), daruna-
vir (DRV), atazanavir (ATV), and etravirine (ETV) were graphically extrapolated from mea-
sured concentrations, using population pharmacokinetic models previously published [15–17].
Reference values for efavirenz (EFV) were adopted from a study fromMarzolini et al. [18]. The
median trough concentrations for these agents in HIV-infected persons receiving the recom-
mended dose are taken from the guidelines for the use of antiretroviral agents in HIV-1
infected adults and adolescents [19].
To measure silibinin plasma concentration, the plasma concentrations of silibinin isomers
(A and B) and silibinin dihydrogen succinate isomers (A and B) were determined by LC/
MS-MS. Of note, the range of plasma concentrations of the LC-MS/MS assay was selected
according to the levels reported in the study from Sala et al [20]. Briefly, 100 μl of plasma was
added to 20 μl of internal standard naringenin (IS) and extracted by protein precipitation.
After evaporation and reconstitution, 20 μL was injected into a Select- HSS T3 (2.1x75 mm,
3.5 μm) (Waters, Milford, MA, USA).
Chromatographic separations were performed using a gradient program with 10 mM
ammonium formate containing 0.1% formic acid and acetonitrile with 0.1% formic acid. Ana-
lytes were quantified by electrospray ionization-triple quadrupole mass spectrometry using the
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selected reaction monitoring detection in the negative mode. Importantly, the selected gradient
program allows adequate separation to quantify isomers A and B individually. The method has
a mean inter-day coefficient of variation (CV) % of<10% and an inter-day deviation from
nominal values of<7%.
Statistical analysis
We used an intention-to-continue treatment approach to calculate virologic responses as per-
centage of patients with undetectable HCV-RNA, using all patients who started treatment as
denominator. Plasma concentrations are presented as median (range). Two-tailed paired t-
tests were conducted to detect difference in trough levels of antiretroviral drugs between pre-
and post-administration of silibinin. GraphPad Prism 6 (GraphPad Software, La Jolla, CA) was
used with an alpha of 0.05.
Results
Patient characteristics
The 16 patients had a median age of 50 years (range 38–60) (Table 1). The most prevalent
HCV transmission mode was via intravenous drug use (n = 12), followed by sexual transmis-
sion (n = 2), contaminated blood products (n = 1), and unknown (n = 1). All patients were on
fully suppressive antiretroviral therapy (ART) (i.e.,<20 HIV-RNA copies/mL plasma), and
had a median CD4+ T-cell count of 586 cells/μL (range 175–2529). Fourteen patients (88%)
were infected with HCV genotype 1a, and one each with genotypes 1b and 1e. Nine patients
(57%) had a METAVIR fibrosis score F4, five (31%) F3, and two (12%) F2. Previous peginter-
feron-ribavirin therapy in the 16 patients elicited 11 non-responses, 4 partial responses, and
Table 1. Baseline characteristics of sixteen HIV/HCV coinfected patients.
Patient Age Sex CD4+ ART GT METAVIR Fibroscan Preceding Tx
years cells/μL kPa
1 49 m 396 RAL,ATV/r,TDF 1a F3 35.8 NR
2 48 f 520 RAL,TDF/FTC 1e F3 19.8 NR
3 50 m 627 RAL,ATV/r,TDF 1a F3 18.4 Breakthrough
4 47 m 686 RAL,ABC/3TC 1b F3 NA PR
5 38 m 175 RAL,EFV,TDF 1a F3 24.6 NR
6 50 m 504 ATV/r,RAL,TDF/FTC 1a F4 17.3 PR
7 45 m 433 RAL,TDF/FTC 1a F4 12 NR
8 53 m 726 ATV/r,TDF/FTC 1a F4 43.1 PR
9 44 m 501 ATV/r,RAL,TDF/FTC 1a F4 14.4 NR
10 48 m 430 ATV/r,RAL,TDF 1a F4 37.4 NR
11 56 m 378 ETR,TDF/FTC 1a F2 6.3 PR
12 52 m 248 RAL,TDF/FTC 1a F4 17.3 NR
13 60 m 744 DRV/r,TDF/FTC 1a F2 5.8 NR
14 43 m 2529 RAL,TDF/FTC 1a F4 13.8 NR
15 51 f 586 RAL,TDF/FTC 1a F4 8.8 NR
16 55 m 1198 DRV/r,TDF/FTC,ETR 1a F4 6.8 NR
Abbreviations: ART: antiretroviral therapy; GT: genotype; Tx: therapyNR: null response; PR: partial responseRAL: raltegravir; ATV/r: atazanavir/ritonavir;
EFV: efavirenz; TDF: tenofovir; FTC: emtricitabine; 3TC: lamivudine; ABC: abacavir; DRV/r: darunavir/ritonavir; ETR: etravirine
doi:10.1371/journal.pone.0133028.t001
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one viral breakthrough. The ART regimens of the patients included ATV, DRV, RAL, EFV,
tenofovir (TDF), emtricitabine (FTC), abacavir (ABC), and lamivudine (3TC).
Drug levels of Silibinin and concurrent antiretroviral therapy
Plasma concentrations for silibinin A, B isomers, silibinin dihydrogen succinate A, B isomers
and antiretroviral drug levels were measured at several occasions at days 1 and 12 for Cmax and
days 2, 4, 8, 12, and 15 for Cmin. Median (range) trough levels for silibinin A, B isomers and sili-
binin dihydrogen succinate A, B isomers are reported in Table 2. Of note, the Cmin of isomer A
of both silibinin dihydrogen succinate and silibinin were 2- and 7-fold higher than the corre-
sponding values of isomer B [20].
Most patients received RAL (n = 13) in combination with ATV/r (n = 5), EFV (n = 1), or
DRV/r (n = 1). ETV was prescribed in 2 patients, combined with DRV/r in one participant.
Among the 16 patients who completed the study, ART plasma levels are reported for 15
patients. One patient was excluded, because there was no plasma sample for drug level mea-
surement available. As depicted in Fig 2, trough levels of the antiretroviral drugs ATV/r and
RAL were not influenced by silibinin coadministration (p = 0.89, p = 0.90, respectively). Simi-
larly, ETV, EFV, and DRV/r plasma levels were not influenced by silibinin administration
(p = 0.14).
HCV and HIV RNA during silibinin lead-in and HCV triple therapy
During the 14 days of intravenous silibinin therapy, HCV RNA declined by>5 log10 IU/mL
(n = 1), 3–5 (n = 2), 2–3 log10 IU/mL (n = 12), and 1–2 log10 IU/mL (n = 1); the median inter-
quartile range (IQR) of HCV RNA decline was 2.65 (2.1–2.8) log10 IU/mL (Fig 3). After the sili-
binin lead-in therapy and initiation of triple therapy, 13 of 16 patients (81%) reached a HCV
RNA below the limit of detection at week 2 of triple-therapy, 15 of 16 patients (94%) at week 4
of triple therapy, and 15 of 16 patients (94%) had undetectable HCV RNA at week 12 of triple
therapy. Eleven of sixteen patients (69%) had an end-of-treatment-response (i.e., undetectable
HCV RNA at week 48), and 10 of 16 patients (63%) showed a SVR 12 thereafter (Fig 3).
Of all sixteen study-participants, six patients (37%) did not reach SVR 12: One patient had a
rapid virologic response (RVR) but stopped treatment at week 8 due to major depression. Five
patients had a RVR, but experienced a viral breakthroughs at week 21, 22, 25, or 32, or a relapse
at week 52. The HIV RNA remained suppressed in all patients during the complete treatment
period, and at SVR 12.
Adverse events and laboratory abnormalities during silibinin treatment
Intravenous silibinin treatment was well tolerated in all patients without any serious adverse
events (Table 3). Mild or moderate adverse events occurred in 14 of 16 patients (88%), includ-
ing sensations of heat (n = 7), headaches (n = 3), nausea (n = 1), diarrhoea (n = 1), and mild
exanthema (n = 1). The most frequent laboratory abnormality observed was an increase in
Table 2. Median Plasma concentrations (range) of silibinin, dihydrogen succinate silibinin and their
respective isomers A and B.
Median Cmax (Range) (μg/mL) Median Cmin (range) (μg/mL)
Silibinin A 0.62 (0.29–1.07) 0.09 (0–0.48)
Silibinin B 0.25 (0.08–0.78) 0.012 (0–0.22)
Dihydrosuccinate silibinin A 81.54 (24.94–7602) 1.03 (0–18.59)
Dihydrosuccinate silibinin B 71.31 (11.15–1971) 0.097 (0–16.15)
doi:10.1371/journal.pone.0133028.t002
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bilirubin in 11 of 16 patients (69%) with a peak level of 78μmol/L (normal range:<21), how-
ever, this increase was not clinically significant and resolved spontaneously after the end of sili-
binin treatment. No abnormalities in full blood count, transaminases or kidney function
occurred during silibinin treatment.
Discussion
We demonstrated as a proof of concept that an intravenous silibinin lead-in was safe, well
tolerated and highly effective in a difficult-to-treat patient population and resulted in a pro-
nounced HCV RNA decline during the lead-in phase. The subsequent initiation of telaprevir-
based triple-therapy led to a SVR 12 in ten of sixteen (63%) HIV/HCV-coinfected patients
with advanced liver fibrosis/cirrhosis and previous failure of peginterferon-ribavirin.
We recently published data on the first six patients treated with a silibinin lead-in followed
by triple-therapy and reported an SVR rate of 80% [12]. Meanwhile ten additional patients
were treated with a silibinin lead-in. One patient discontinued treatment due to side effects and
another four patients experienced viral breakthrough. Thus, the SVR rate decreased to 63%.
However, a SVR 12 of 63% is still remarkably high compared with reported treatment out-
comes in similar patient groups. Data from the CUPIC trial revealed that only 20% of the
patients with cirrhosis who did not respond to previous peginterferon-ribavirin treatment
achieved an SVR with triple therapy [21]. The REALIZE trial reported on-treatment virologic
failure in up to 50% of patients [22]. Virologic failure could be driven by the development of
Fig 2. Plasma trough concentrations in patients before (day 1) and during (day 12) silibinin treatment.
A Raltegravir levels (n = 10) B Atazanavir plasma levels (n = 5) C x—-x Efavirenz (n = 1) ●—- ●Darunavir
(n = 2) —-Etravirine (n = 2).
doi:10.1371/journal.pone.0133028.g002
Fig 3. HCV-RNA viral load in sixteen patients during lead-in therapy with intravenous silibinin treatment for 2 weeks followed by triple-therapy for
12 weeks.One patient discontinued treatment due to major depression before week 8. Five patients experienced viral breakthroughs at weeks 21, 22, 28,
32, or 52.RVR: rapid virologic response; EVR: early virologic response; EOTR: end of treatment response; SVR: sustained virologic response; PR: pegylated
interferon and ribavirin.
doi:10.1371/journal.pone.0133028.g003
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HCV protease inhibitor resistance and the insensitivity of the hepatic cells to peginterferon-
ribavirin [23]. We hypothesize that the higher SVR rate in our patient group is mainly related
to the lead-in treatment with silibinin. Silibinin led to a rapid HCV RNA decline and presum-
ably prevented the development of resistance against telaprevir. An additional explanation
might be that treatment discontinuations due to triple-therapy related side effects were very
rare in our cohort and occurred in only one patient (6%). A European cohort including diffi-
cult-to-treat coinfected patients recently reported treatment discontinuations in 5 of 21
patients (23%) due to side effects [24].
We acknowledge that in the light of the extremely potent and well tolerated next-generation
DAAs the current value of silibinin for treatment of HCV infection is limited [25]. However, as
a proof of concept we demonstrated that a silibinin lead-in was very effective and very well tol-
erated in difficult-to-treat HIV/HCV coinfected patients and caused no significant drug-drug
interactions. To the best of our knowledge, the plasma concentrations of silibinin isomers and
prodrugs (silibinin dihydrogen succinate A and B) are reported for the first time in HIV/HCV
coinfected patients. These levels provide information about the range of Cmax and Cmin
observed in this population and indicate the wide variability between individuals. The finding
that silibinin does not influence the pharmacokinetics of antiretroviral drugs is in line with a
previous report fromMolto et al. [26].
We would like to share our data since a silibinin add-on could have some benefit in special
clinical settings for selected patients: First, in HIV/HCV coinfected patients on salvage ART in
whom significant drug-drug interactions may limit the use of some newer DAAs. For example,
HIV protease inhibitors cannot be administrated together with the HCV protease inhibitor
simeprevir or with the new compounds MK-5172 and MK 8742 [6, 25, 27]. Second, to improve
treatment success with DAAs and/or prevent development of resistance to DAAs with a low
resistance barrier [28]. Third, in patients not tolerating newer DAAs but in clinical need for
immediate treatment. However, further studies should be done including these selected popu-
lations to determine how best to use silibinin to improve outcomes for these difficult-to-treat
patients.
Apart from its anti-HCV effect, silibinin shows a broad-spectrum antiviral activity in vitro
and therefore might serve as an investigational antiviral agent in the setting of life-threatening,
to date untreatable viral diseases (e.g., severe respiratory syncytial virus infections in
Table 3. Adverse events and laboratory abnormalities during silibinin treatment.
Event Number of patients (%)n = 16
Discontinuation because of an adverse event 0
Any serious adverse event 0
Any adverse event 14 (88)
Adverse event probably or deﬁnitely related to silibinin1 13 (81)
Sensation of heat during silibinin infusion 7 (44)
Headache 3 (19)
Nausea 1 (6)
Diarrhoea 1 (6)
Mild exanthema 1 (6)
Laboratory abnormalities
>1.5x increase in bilirubin2 11 (69)
1 All adverse events were of mild or moderate intensity and resolved spontaneously
2 The Increase in bilirubin was clinically not signiﬁcant and resolved spontaneously
doi:10.1371/journal.pone.0133028.t003
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immunocompromised patients) [29, 30]. In addition, silibinin is reported to have potential as a
hepatitis B/hepatitis delta entry inhibitor through down-regulation of virus specific receptors
and effects on envelope proteins [31], and as therapeutic agent for treatment of non-alcoholic
fatty liver disease and alcoholic liver cirrhosis [32, 33]. The possible uses of silibinin may
become even more interesting once this drug becomes available as oral regimen with the ability
to achieve high serum concentrations.
In conclusion, a lead-in course with intravenous silibinin prior to the initiation of triple-
therapy resulted in a 63% SVR 12 rate in ten of sixteen HIV/HCV coinfected patients with
advanced liver fibrosis and previous failure to peginterferon-ribavirin. Tolerability and safety
of silibinin was favorable and no significant drug-drug interactions with ART occurred. Due to
its anti-viral and anti-inflammatory properties, silibinin may serve in the future as part of the
cure for hepatitis C and other viral infections and liver diseases.
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